Body composition as predictor of toxicity and outcomes in patients with metastatic non-small cell lung cancer (mNSCLC) receiving nivolumab (Nivo).
Shlomit Strulov Shachar(Tel Aviv University), Mira Wollner(Technion – Israel Institute of Technology), Itamar Shafran(Tel Aviv University), Gil Bar‐Sela(Emek Medical Center), Rachel Fried(Rambam Health Care Campus), Anat Reiner‐Benaim(Rambam Health Care Campus), Mor Moskovitz(Rambam Health Care Campus), Grant R. Williams(University of Alabama at Birmingham)
Cited by 7
Related Papers
BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors
|Journal of Thoracic Oncology|2018|220
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous <i>EGFR</i> -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial
|Journal of Clinical Oncology|2024|131
Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data
|Lung Cancer|2017|104
ALK-Rearranged Non–Small-Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism
|Clinical Lung Cancer|2016|100
UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)
|Journal of Thoracic Oncology|2022|97